Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,080.60 -14.39 (-1.31%)
Streaming Delayed Price Updated: 11:25 AM EDT, Jul 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
32 33 Next >
Adagio Continues Its Run As Biotech Stocks Moderna, BioNTech Dive On Omicron Threat
Biotech stocks diverged Tuesday with Adagio continuing a run on the potential for its antibody to target Covid's omicron variant. 
Via Investor's Business Daily
Retail Stocks Trading Lower on Weaker Black Friday Numbers
After Friday’s Omicron variant sell-off, things were looking pretty bleak for investors, but stocks rallied back on Monday. The Nasdaq Composite (COMP:GIDS) led... 
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Cumberland Gets FDA Approval For IV-Delivered Ibuprofen For Use In Pre-... 
Via Benzinga
Exposures Product Safety
ADGI Stock Soars as Analysts Lock On to Its Omicron-Fighting Potential
Shares of ADGI stock are soaring higher by 80% after the company stated that its ADG-20 antibody is effective against the omicron variant. 
Via InvestorPlace
Exposures COVID-19
Adagio shares soar on antibody potential against new COVID variant omicron
Stifel analyst Stephen Willey believes vaccines alone are unlikely to sufficiently address the COVID-19 pandemic. 
Via Talk Markets
Exposures COVID-19
3 Pharma Stocks Morgan Stanley Says Will Be Omicron Variant Beneficiaries
The news of a new variant of the coronavirus Friday sent financial markets into a tailspin. The adversity could present an opportunity for a h... 
Via Benzinga
Exposures COVID-19
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
Regeneron Extends Hearing Loss Gene Therapy pact With Decibel
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover... 
Via Benzinga
Why Regeneron's Results for Its COVID Antibody Therapy Won't Boost Sales Much
The therapy will likely face stiff competition from more convenient COVID-19 pills. 
Via The Motley Fool
Exposures COVID-19
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack... 
Via Benzinga
Stocks Most Impacted by 7-10 Year Treasuries
A look at S&P 500 members that perform best when the iShares 7-10 Year Treasury Bonds ETF (IEF) loses value. 
Via Talk Markets
Topics Stocks
Exposures US Equities
A Peek Into The Markets: US Stock Futures Higher Ahead Of Tyson Foods Earnings
Pre-open movers U.S. stock futures traded higher in early pre-market trade after closing higher in the prior session. Investors are awaiting earnings results from Tyson Foods,... 
Via Benzinga
5 Stocks To Watch For November 15, 2021
Some of the stocks that may grab investor focus today are: Wall Street expects Warner Music Group Corp. (NYSE: WMG) to report quarterly earnings at $0.15 per share on revenue... 
Via Benzinga
Large Cap Biopharmaceuticals Metrics and Review: JNJ Splits Up
Today JNJ announced a split of the Company separating its legacy consumer products from higher growth growing biopharmaceutical and medtech products. 
Via Talk Markets
Europe Approves Regeneron - Roche's COVID-19 Antibody Cocktail
The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and... 
Via Benzinga
Exposures COVID-19
Ligand Pharmaceuticals Sees RS Rating Rise To 92
A Relative Strength Rating upgrade for Ligand Pharmaceuticals shows improving technical performance. 
Via Investor's Business Daily
EU Regulator Backs Regeneron-Roche's COVID-19 Drug
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc... 
Via Benzinga
Exposures COVID-19
When Winning Streaks Stop: Trying To Beat The Market By Buying Stocks Like Tesla
Teslas getting charged in a Wawa parking lot last month. Photo via author. When Winning Streaks Stop In a post in August (Tesla And The Quest For Alpha), we wrote about how a... 
Via Benzinga
Regeneron-Roche's COVID-19 Treatment Shows Long Term Benefit After Single Dose
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg... 
Via Benzinga
Exposures COVID-19
When Winning Streaks Stop
Trying to beat the market by buying stocks like Tesla. It's probably impossible to time these things perfectly, but as we continue to collect data, we may be able to spend more time in winning... 
Via Talk Markets
Wall Street Crime and Punishment: Martin Shkreli, The Self-Destructive Pharma Bro
Does crime pay? Wall Street Crime and Punishment is a weekly series by Benzinga's Phil Hall chronicling the bankers, brokers and financial ne’er-do-wells whose ambition... 
Via Benzinga
What 8 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021
Upgrades For IGM Biosciences Inc (NASDAQ: 
Via Benzinga
A Deep Dive Into COVID Oral Treatments — What Does the Atea Failure Mean for Oral Antivirals?
Photo by Danilo Alvesd on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
3 Reasons Why Investors Should Love Regeneron's Q3 Update
The big biotech delivered an exceptionally strong performance in Q3. 
Via The Motley Fool
Regeneron Pharmaceuticals Inc (REGN) Q3 2021 Earnings Call Transcript
REGN earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
7 European Stocks to Buy to Diversify Your Portfolio
While exposure to U.S.-based securities continues to be a good idea, you can diversify your opportunities by considering European stocks. 
Via InvestorPlace
Regeneron Pharmaceuticals Earnings Perspective: Return On Invested Capital
Pulled from Benzinga Pro data, Regeneron Pharmaceuticals (NASDAQ:REGN) posted Q3 earnings of $1.85 billion, an increase from Q2 of 44.81%. Sales dropped to $3.45 billion, a 32.81... 
Via Benzinga
Why Regeneron Shares Are Rising Today
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) is trading higher Thursday after the company announced better-than-expected third-quarter financial results. Regeneron reported... 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.